BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Repatha (Evolocumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Repatha (Evolocumab)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06496243-1032@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Repatha (Evolocumab): Phase 2 readout est. (NCT06496243)
DESCRIPTION:Repatha (Evolocumab)\, phase 2\, Atherosclerotic Cardiovascular
  Disease.\nStudy: Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp
 (a) Levels\nEstimated primary completion: November 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/evolocumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06496243
URL:https://assetmemo.bio/drug/evolocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388420-1032@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Repatha (Evolocumab): Phase na readout est. (NCT07388420)
DESCRIPTION:Repatha (Evolocumab)\, phase na\, Atherosclerotic Cardiovascula
 r Disease.\nStudy: Adding Evolocumab to Conventional Lipid-lowering Therap
 y for Hypertriglyceridemia Induced Acute Pancreatitis\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/evolocumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07388420
URL:https://assetmemo.bio/drug/evolocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05152888-1032@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Repatha (Evolocumab): Phase 4 readout est. (NCT05152888)
DESCRIPTION:Repatha (Evolocumab)\, phase 4.\nStudy: The Impact of Pcsk-9 In
 hibition on PET CFR in Patients at High CV Risk\nEstimated primary complet
 ion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 volocumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05152888
URL:https://assetmemo.bio/drug/evolocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05284747-1032@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270529
DTEND;VALUE=DATE:20270530
SUMMARY:Repatha (Evolocumab): Phase 4 readout est. (NCT05284747)
DESCRIPTION:Repatha (Evolocumab)\, phase 4.\nStudy: EVOLVE-MI: EVOLocumab V
 ery Early After Myocardial Infarction\nEstimated primary completion: 29 Ma
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/evolocumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT052847
 47
URL:https://assetmemo.bio/drug/evolocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05641753-1032@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Repatha (Evolocumab): Phase 4 readout est. (NCT05641753)
DESCRIPTION:Repatha (Evolocumab)\, phase 4.\nStudy: Cholesterol Lowering an
 d Residual Risk in Diabetes\, Type 1\nEstimated primary completion: 1 July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/evolocumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0564175
 3
URL:https://assetmemo.bio/drug/evolocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284564-1032@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Repatha (Evolocumab): Phase 2 readout est. (NCT06284564)
DESCRIPTION:Repatha (Evolocumab)\, phase 2.\nStudy: A Phase II Study Bolste
 ring Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and N
 ivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)\nEst
 imated primary completion: 1 October 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/evolocumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06284564
URL:https://assetmemo.bio/drug/evolocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612774-1032@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Repatha (Evolocumab): Phase 4 readout est. (NCT07612774)
DESCRIPTION:Repatha (Evolocumab)\, phase 4\, Atherosclerotic Cardiovascular
  Disease.\nStudy: CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolo
 cumab After ACS\nEstimated primary completion: 31 October 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/evolocumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07612774
URL:https://assetmemo.bio/drug/evolocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081153-1032@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Repatha (Evolocumab): Phase 1 readout est. (NCT06081153)
DESCRIPTION:Repatha (Evolocumab)\, phase 1.\nStudy: Mechanistic Clinical Tr
 ial of PCSK9 Inhibition for AAA\nEstimated primary completion: 15 January 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/evolocumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06081153
URL:https://assetmemo.bio/drug/evolocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803679-1032@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Repatha (Evolocumab): Phase 4 readout est. (NCT07803679)
DESCRIPTION:Repatha (Evolocumab)\, phase 4\, Atherosclerotic Cardiovascular
  Disease.\nStudy: A Trial Assessing the Effectiveness of Evolocumab in Red
 ucing the Plaque Burden in Participants With Subclinical Atheroma\nEstimat
 ed primary completion: 30 April 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/evolocumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07803679
URL:https://assetmemo.bio/drug/evolocumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
